US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...
A new study reveals that scratching is not just an annoying reflex — it plays a dual role in immune activation and pathogen ...
An AI-enabled wearable sensor with vibratory feedback significantly reduces nocturnal scratching in atopic dermatitis, ...
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Is chronic overwhelm disrupting your work, wellbeing and relationships? Here's how to bring some calm and balance into your ...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Odell Beckham Jr. revealed he was diagnosed with a chronic skin condition known as seborrheic dermatitis that causes itching.
Dryness between the fingers can be an uncomfortable and sometimes persistent issue but with the right care and preventive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback